Therapeutic subgroup
L02 – ENDOKRINE THERAPIE
- Anatomical main group L: ANTINEOPLASTISCHE UND IMMUNMODULIERENDE MITTEL
14Decisions
21Patient groups
Added benefit by patient group
- Considerable8
- Minor2
- Not proven11
Subgroups
- L02B HORMONANTAGONISTEN UND VERWANDTE MITTEL 14 decisions
Decisions, newest first
- 2026-02-19NubeqaDarolutamidNot proven
- 2024-05-02OrserduElacestrantConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-09-21NubeqaDarolutamidConsiderable
- 2023-04-06OrgovyxRelugolixNot proven: 5 of 5 patient groups
- 2021-11-19XtandiEnzalutamidNot proven
- 2020-11-05XtandiEnzalutamidMinor
- 2020-10-15NubeqaDarolutamidConsiderable
- 2020-10-01ErleadaApalutamidMinor
- 2020-08-20ErleadaApalutamidNot proven
- 2018-06-07ZytigaAbirateronacetatConsiderable
- 2015-06-18XtandiEnzalutamidConsiderable
- 2014-02-20XtandiEnzalutamidConsiderable
- 2013-07-04ZytigaAbirateronacetatConsiderable
- 2012-03-29ZytigaAbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
Data status: 2026-10-29